Drug intelligence / Profile preview

RG7667

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**RG7667** is an investigational intravenous anti-cytomegalovirus combination therapy developed by Genentech. It contains two anti-CMV immunoglobulin G1 monoclonal antibodies, MCMV5322A and MCMV3068A, designed to neutralize human cytomegalovirus by binding viral envelope glycoprotein complexes and blocking viral entry into susceptible host cells. It was evaluated through Phase 2 for prevention of cytomegalovirus infection and disease in high-risk kidney-transplant recipients. ([journals.asm.org](https://journals.asm.org/doi/10.1128/aac.01108-17))

Brand names: RG7667RG-7667RG 7667
Other names: MCMV5322A + MCMV3068A

Targets

HCMV Pentamer (HCMV pentameric glycoprotein complex)GH (Growth hormone)

Beyond the preview

Go deeper on RG7667.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG7667.

Explore the full profile